Dr Agarwals Eye Hospital (DRAGARWQ)₹5,553+2.75%Hospital
In the Jun 2026 quarter (standalone), Dr Agarwals Eye Hospital reported sales of ₹143 Cr, up 22.2% from Jun 2025, and net profit of ₹22.97 Cr, up 35.3% year on year. For the year to Mar 2026, sales were ₹470 Cr and net profit ₹69.93 Cr.
Company filings, standalone accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 83.82 | 75.90 | 80.81 | 99.89 | 102 | 94.81 | 99.74 | 117 | 118 | 116 | 120 | 143 |
| Expenses | 61.01 | 55.07 | 56.06 | 69.01 | 72.07 | 69.01 | 68.06 | 80.04 | 78.09 | 82.01 | 86.10 | 100 |
| Operating Profit | 23.09 | 21.06 | 24.06 | 31.12 | 30.11 | 26.08 | 32.08 | 37.09 | 40.14 | 34.12 | 34.10 | 43.15 |
| OPM % | 28.0% | 27.0% | 30.0% | 31.0% | 29.0% | 27.0% | 32.0% | 32.0% | 34.0% | 30.0% | 28.0% | 30.0% |
| Other Income | 0.99 | 0.99 | 1.99 | 0.00 | 1.99 | 1.99 | 0.00 | 0.99 | 0.99 | 2.99 | 1.99 | 1.99 |
| Interest | 1.99 | 1.99 | 1.99 | 2.99 | 3.99 | 3.99 | 2.99 | 3.99 | 3.99 | 1.99 | 1.99 | 2.99 |
| Depreciation | 6.01 | 7.01 | 8.01 | 9.99 | 9.01 | 10.01 | 9.99 | 10.99 | 11.01 | 12.01 | 12.01 | 10.99 |
| Profit before tax | 17.07 | 13.05 | 17.05 | 19.06 | 19.05 | 14.05 | 19.05 | 23.09 | 26.08 | 23.07 | 21.08 | 31.13 |
| Tax % | 24.1% | 26.1% | 26.1% | 25.1% | 26.1% | 26.1% | 14.1% | 26.1% | 25.1% | 26.1% | 24.1% | 24.1% |
| Net Profit | 12.98 | 8.99 | 12.97 | 13.97 | 13.97 | 9.98 | 15.96 | 16.98 | 18.96 | 16.97 | 15.98 | 22.97 |
| EPS (Rs) | 26.86 | 20.14 | 27.28 | 30.09 | 30.17 | 22.18 | 34.10 | 36.82 | 40.05 | 35.86 | 33.70 | 48.51 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 137 | 149 | 153 | 170 | 176 | 140 | 200 | 267 | 318 | 396 | 470 | 496 |
| Expenses | 119 | 126 | 129 | 140 | 129 | 109 | 143 | 192 | 227 | 277 | 326 | 346 |
| Operating Profit | 18.05 | 23.09 | 24.07 | 30.10 | 47.13 | 31.10 | 59.22 | 76.29 | 92.23 | 120 | 145 | 152 |
| OPM % | 13.0% | 15.0% | 16.0% | 18.0% | 27.0% | 22.0% | 29.0% | 28.0% | 29.0% | 30.0% | 31.0% | 30.5% |
| Other Income | −4.99 | 0.99 | 1.99 | 1.99 | 2.99 | 0.99 | 0.99 | 1.99 | 4.98 | 4.98 | 5.98 | 7.96 |
| Interest | 4.99 | 3.99 | 2.99 | 3.99 | 8.98 | 6.98 | 6.99 | 7.99 | 7.99 | 14.96 | 11.97 | 10.96 |
| Depreciation | 8.99 | 8.99 | 9.99 | 10.99 | 21.01 | 18.99 | 19.98 | 19.99 | 27.01 | 38.98 | 46.02 | 46.02 |
| Profit before tax | 0.00 | 11.03 | 13.04 | 17.07 | 20.06 | 6.02 | 32.08 | 49.14 | 62.17 | 71.19 | 94.37 | 101 |
| Tax % | −103.9% | 33.1% | 49.1% | 32.1% | 31.1% | 125.1% | 25.1% | 25.1% | 26.1% | 23.1% | 25.1% | — |
| Exceptional items | −2.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.00 | — |
| Net Profit | 0.00 | 6.99 | 6.98 | 11.99 | 13.98 | −0.99 | 23.96 | 36.94 | 45.91 | 54.88 | 69.93 | 74.88 |
| EPS (Rs) | 0.10 | 15.66 | 14.47 | 25.44 | 29.19 | −3.07 | 51.40 | 78.79 | 98.89 | 116.54 | 145.50 | 158.12 |
| Dividend payout % | 940.0% | 10.0% | 8.0% | 6.0% | 0.0% | 0.0% | 6.0% | 4.0% | 3.0% | 5.0% | 3.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.01 | 5.01 | 5.01 | 5.01 | 5.01 | 5.01 | 5.01 | 5.01 | 5.01 | 5.01 | 5.01 | 5.01 |
| Reserves | 18.99 | 18.96 | 24.97 | 29.98 | 40.94 | 51.00 | 50.00 | 72.89 | 109 | 152 | 205 | 341 |
| Borrowings | 27.03 | 31.02 | 23.02 | 18.02 | 24.00 | 60.06 | 68.06 | 193 | 232 | 268 | 333 | 327 |
| Other Liabilities | 18.09 | 24.12 | 20.09 | 28.14 | 31.15 | 24.12 | 33.16 | 42.21 | 44.22 | 71.35 | 71.34 | 94.45 |
| Total Liabilities | 69.12 | 79.11 | 72.09 | 81.15 | 100 | 141 | 155 | 314 | 391 | 497 | 614 | 767 |
| Fixed Assets | 26.02 | 34.05 | 33.03 | 36.04 | 55.03 | 94.13 | 96.12 | 214 | 260 | 316 | 393 | 404 |
| CWIP | 0.00 | 1.01 | 1.01 | 3.01 | 0.00 | 0.00 | 0.00 | 26.05 | 62.05 | 97.15 | 128 | 197 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.98 | 88.78 |
| Other Assets | 43.10 | 44.05 | 38.05 | 42.10 | 45.07 | 47.06 | 60.11 | 73.15 | 67.16 | 83.15 | 80.09 | 78.11 |
| Inventories | 10.37 | 9.85 | 6.12 | 7.32 | 6.48 | 7.97 | 5.20 | 5.72 | 5.99 | 9.73 | 13.37 | 14.08 |
| Trade receivables | 6.04 | 9.06 | 6.62 | 7.06 | 8.62 | 6.76 | 8.76 | 8.66 | 10.09 | 12.90 | 13.94 | 18.68 |
| Cash & equivalents | 1.90 | 2.43 | 2.86 | 2.40 | 4.87 | 6.89 | 22.24 | 28.83 | 28.11 | 33.80 | 12.18 | 6.72 |
| Total Assets | 69.12 | 79.11 | 72.09 | 81.15 | 100 | 141 | 155 | 314 | 391 | 497 | 614 | 767 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 14.01 | 16.99 | 19.99 | 19.01 | 25.03 | 38.99 | 34.02 | 56.99 | 70.03 | 90.04 | 94.02 | 145 |
| Cash from investing activity | −10.01 | −17.02 | −8.01 | −11.01 | −25.01 | −16.99 | −11.01 | −46.04 | −71.05 | −70.04 | −133 | −174 |
| Cash from financing activity | −5.01 | 0.00 | −12.02 | −8.01 | 2.01 | −20.03 | −8.01 | −4.01 | 0.00 | −14.02 | 17.03 | 25.03 |
| Net cash flow | −1.01 | 0.00 | 0.00 | 0.00 | 2.01 | 2.01 | 15.02 | 7.01 | −1.01 | 6.01 | −22.02 | −4.01 |
| Capex | 11.04 | 17.05 | 9.03 | 11.04 | 25.08 | 17.06 | 11.04 | 47.19 | 70.27 | 71.22 | 103 | 98.40 |
| Free cash flow | 2.99 | 0.99 | 11.98 | 6.98 | 0.00 | 21.97 | 22.97 | 9.98 | −0.99 | 18.98 | −7.99 | 46.92 |
| CFO / OP % | 106.0% | 113.0% | 103.1% | 98.0% | 111.0% | 96.1% | 120.0% | 112.0% | 107.0% | 112.0% | 95.0% | 106.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 18 | 23 | 15 | 16 | 18 | 13 | 22 | 15 | 13 | 14 | 12 | 13 |
| Inventory days | 238 | 200 | 123 | 148 | 124 | 132 | 117 | 91 | 73 | 106 | 117 | 109 |
| Days payable | 359 | 370 | 276 | 352 | 291 | 223 | 400 | 409 | 326 | 344 | 262 | 207 |
| Cash conversion cycle | −104 | −147 | −139 | −190 | −150 | −79 | −261 | −304 | −241 | −225 | −134 | −85 |
| Working capital days | −30 | −38 | −24 | −38 | −21 | −33 | −69 | −57 | −49 | −62 | −50 | 15 |
| ROCE % | 19.1% | 18.1% | 29.1% | 32.1% | 34.1% | 30.1% | 11.1% | 20.1% | 19.1% | 18.1% | 18.1% | 17.1% |
For the Jun 2026 quarter, Dr Agarwals Eye Hospital reported sales of ₹143 Cr, up 22.2% year on year and net profit of ₹22.97 Cr, up 35.3% year on year. The operating margin was 30.0%.
Dr Agarwals Eye Hospital's sales for the year to Mar 2026 were ₹470 Cr; over the last twelve months they were ₹496 Cr.
Net profit for the year to Mar 2026 was ₹69.93 Cr, and ₹74.88 Cr over the last twelve months. Earnings per share over the same trailing period were ₹158.12.
Dr Agarwals Eye Hospital reported borrowings of ₹327 Cr at Mar 2026, against cash and equivalents of ₹6.72 Cr.
Cash from operations was ₹145 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹46.92 Cr.